These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The pharmocogenomics of warfarin: closing in on personalized medicine. Rettie AE; Tai G Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144 [TBL] [Abstract][Full Text] [Related]
3. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Schwarz UI; Stein CM Clin Pharmacol Ther; 2006 Jul; 80(1):7-12. PubMed ID: 16815312 [No Abstract] [Full Text] [Related]
4. Warfarin monitoring woes: a glimmer of hope with pharmacogenomics. Beier MT J Am Med Dir Assoc; 2008 Mar; 9(3):199-200. PubMed ID: 18294604 [No Abstract] [Full Text] [Related]
5. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Yin T; Miyata T Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452 [TBL] [Abstract][Full Text] [Related]
9. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Scott SA; Edelmann L; Kornreich R; Desnick RJ Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229 [TBL] [Abstract][Full Text] [Related]
10. Refining the use of warfarin through genetic testing. Lee SC Int Angiol; 2008 Aug; 27(4):271-3. PubMed ID: 18677287 [No Abstract] [Full Text] [Related]
11. Genetic testing for warfarin dosing? Not yet ready for prime time. Bussey HI; Wittkowsky AK; Hylek EM; Walker MB Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960 [No Abstract] [Full Text] [Related]
12. Role of warfarin pharmacogenetic testing in clinical practice. Tan GM; Wu E; Lam YY; Yan BP Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic testing for warfarin dosing: we are ready now. Wu AH Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308 [No Abstract] [Full Text] [Related]
16. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Benusiglio PR; Desmeules J; de Moerloose P; Dayer P Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831 [TBL] [Abstract][Full Text] [Related]
17. Warfarin and pharmacogenomic testing: what would Pascal do? Teagarden JR Pharmacotherapy; 2009 Mar; 29(3):245-7. PubMed ID: 19249943 [No Abstract] [Full Text] [Related]
18. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB; Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of target genes across the warfarin pharmacological pathway. Lal S; Jada SR; Xiang X; Lim WT; Lee EJ; Chowbay B Clin Pharmacokinet; 2006; 45(12):1189-200. PubMed ID: 17112295 [TBL] [Abstract][Full Text] [Related]
20. Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose. Suarez-Kurtz G; Perini JA; Silva-Assunção E; Struchiner CJ Blood; 2009 Apr; 113(17):4125-6. PubMed ID: 19389892 [No Abstract] [Full Text] [Related] [Next] [New Search]